It has long been known that a hallmark of Alzheimer’s disease, and most other neurodegenerative diseases, is the clustering together of insoluble protein aggregates in the brain. During normal disease-free aging, there is also an accumulation of insoluble proteins.
To date, approaches to interventions for Alzheimer’s disease have not addressed the contribution of protein insolubility as a general phenomenon, instead concentrating on one or two insoluble proteins. Buck researchers have recently completed a systematic study in worms that depicts an intricate picture of the connections between insoluble proteins in neurodegenerative diseases and aging. Furthermore, the work demonstrated an intervention that could reverse the deleterious effects of the aggregates by enhancing mitochondrial health.
“Based on our discoveries, targeting insoluble proteins could provide a strategy for the prevention and treatment of a variety of age-related diseases,” said Edward Anderton, PhD, a postdoctoral fellow in Gordon Lithgow’s lab and co-first author of a study that appears in the May 16 issue of the journal GeroScience.
“Our study shows how maintaining healthy mitochondria can combat protein clumping linked to both aging and Alzheimer’s,” said Manish Chamoli, PhD, a research scientist in Gordon Lithgow’s and Julie Andersen’s lab, and co-first author of the study. “By boosting mitochondrial health, we can potentially slow down or reverse these harmful effects, offering new ways to treat both aging and age-related diseases.”
Results Corroborate The Geroscience Hypothesis
The strong link between insoluble proteins promoting normal aging and diseases also establishes a case for the broader picture of how aging and age-related diseases occur. “We would argue that this work really supports the geroscience hypothesis that there is a common pathway to Alzheimer’s disease and aging itself,” said Buck Professor Gordon Lithgow. PhD, Vice President of Academic Affairs and the senior author of the study. “Aging is driving the disease, but the factors that put you on the track toward the disease actually occur very early.”
The fact that the team found a core recalcitrant proteome enriched with numerous proteins that had not been considered before creates new targets for exploration, said Lithgow. “In some ways it raises the flag about whether we should be thinking about what Alzheimer’s looks like in very young people,” he said.
Beyond Amyloid And Tau
The focus of most research on Alzheimer’s disease to date has been targeting accumulations of two proteins: amyloid beta and tau. But there are literally thousands of other proteins in these insoluble aggregations, said Anderton, and their function in Alzheimer’s disease was unknown. Additionally, he added, their lab and others’ have observed that during the normal disease-free aging process there is also an accumulation of intractable proteins. These insoluble proteins from aged animals, when mixed with amyloid beta in the test tube, accelerate the aggregation of the amyloid.
What was the connection between the accumulation aggregates Alzheimer’s and disease-free aging, the team pondered. Focusing on the amyloid beta protein, they used a strain of the microscopic worm Caenorhabditis elegans, long been used in aging studies, that has been engineered to produce human amyloid protein.
Anderton said the team suspected they might see that amyloid beta is driving some level of insolubility in other proteins. “What we found is that amyloid beta causes a massive amount of insolubility, even in a very young animal,” said Anderton. They found that there is a subset of proteins that seem to be very vulnerable to becoming insoluble, either by adding amyloid beta or during the normal aging process. They dubbed that vulnerable subset the “core insoluble proteome”.
The team went on to demonstrate that the core insoluble proteome is full of proteins that have already been linked to various neurodegenerative diseases in addition to Alzheimer’s disease, including Parkinson’s disease, Huntington’s disease and prion disease.
“Our paper shows that amyloid could be acting as a driver of this normal aging aggregation,” said Anderton. “Now we’ve got clear evidence, I think for the first time, that both amyloid and aging are affecting the same proteins in a similar way. It’s quite possibly a pernicious cycle where aging is driving insolubility and amyloid beta is also driving insolubility, and they’re just making each other worse.”
Read Also: Steps to Becoming an Economist
The amyloid protein is very toxic to the worms and the team sought to discover a means to reverse that toxicity. “Since hundreds of mitochondrial proteins become insoluble both during aging and after expressing amyloid beta, we thought if we can boost the mitochondrial protein quality using a compound, then maybe we can reverse some of the negative effects of amyloid beta,” said Anderton. That’s exactly what they discovered, using Urolithin A, a natural gastrointestinal metabolite generated when we consume raspberries, walnuts, and pomegranates which is known to enhance mitochondrial function: it substantially delayed the deleterious effects of amyloid beta.
“Something that was glaringly obvious from our dataset is that the importance of mitochondria keeps coming up,” said Anderton. A conclusion, the authors say, is the reminder that the health of mitochondria is critical to overall health. “Mitochondria have a strong link with aging. They’ve got a strong connection with amyloid beta,” he said. “I think ours is one of the few studies that shows that insolubility and aggregation of those proteins might be the link between the two.”
“Because the mitochondria are so central to all of this, one way to break the vicious cycle of decline is to replace damaged mitochondria with new mitochondria,” said Lithgow. “And how do you do that? You exercise and follow a healthful diet.”
